Rankings
▼
Calendar
UTHR Q2 2021 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena
UTHR
United Therapeutics Corporation
$24B
Q2 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$447M
+23.3% YoY
Gross Profit
$409M
91.7% margin
Operating Income
$222M
49.8% margin
Net Income
$173M
38.7% margin
EPS (Diluted)
$3.65
QoQ Revenue Growth
+17.8%
Cash Flow
Operating Cash Flow
$148M
Free Cash Flow
$132M
Stock-Based Comp.
$29M
Balance Sheet
Total Assets
$4.8B
Total Liabilities
$1.2B
Stockholders' Equity
$3.6B
Cash & Equivalents
$942M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$447M
$362M
+23.3%
Gross Profit
$409M
$336M
+21.8%
Operating Income
$222M
$141M
+58.1%
Net Income
$173M
$107M
+61.2%
Revenue Segments
Tyvaso
$154M
34%
Remodulin
$140M
31%
Orenitram
$76M
17%
Unituxin
$53M
12%
Adcirca
$24M
5%
Geographic Segments
UNITED STATES
$412M
92%
European Union And Others
$35M
8%
← FY 2021
All Quarters
Q3 2021 →